Advisory Committee recommends that U.S. Food and Drug Administration keep rosiglitazone (Avandia) on the market, continue clinical trial of safety and efficacy
15 July 2010
79 views
No Comment
American Heart Association Comment View full post on News releases (Heart News) |
Leave your response!
You must be logged in to post a comment.